Pulmatrix (PULM) Gains from Investment Securities (2014 - 2025)

Pulmatrix (PULM) posted Gains from Investment Securities of -$1000.0 for Q2 2025, up 98.48% sequentially from -$66000.0 in Q1 2025.

Pulmatrix (PULM) Gains from Investment Securities (2014 - 2025) Analysis & Trends

Pulmatrix has reported Gains from Investment Securities for 3 years, with the latest figure at -$1000.0 in Q2 2025.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$1000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$67000.0 (changed N/A YoY) and the FY2025 annual result came in at -$67000.0, down 200.0% from the prior year.
Gains from Investment Securities rose to -$1000.0 in Q2 2025 per PULM's latest filing, from -$66000.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at -$1000.0 in Q2 2025 and troughed at -$66000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Pulmatrix	5.46 Mn	5.46 Mn	-

Download Data